|
イトウ ユウタ
Itoh Yuta
伊東 佑太 所属 リハビリテーション学部 職種 准教授 |
|
| 発表年月日 | 2017/02 |
| 発表テーマ | Application of iPSC-derived Mesenchymal Stromal Cell (MSC) toward Treating Muscular Disease |
| 会議名 | 3rd International Symposium on Regenerative Rehabilitation in Kyoto |
| 学会区分 | 国際学会 |
| 発表形式 | 口頭（一般） |
| 単独共同区分 | 共同 |
| 開催地名 | Kyoto Univ. |
| 発表者・共同発表者 | Nana Takenaka-Ninagawa, Yuta Itoh, Makoto Ikeya, Kim Jin Sol, Rukia Ikeda, Hidetoshi Sakurai. |
| 概要 | Mesenchymal stromal cell (MSC) is well known as a multipotent progenitor for osteogenic, chondrogenic and adipogenic lineage, and is also found in skeletal muscles. Recent studies reported that although they normally act as supportive cells on skeletal muscle homeostasis with producing collagen VI, they are also the responsive cells for fibrosis and fatty degeneration in diseased muscle. Moreover, mutations of Col6 genes, which are specifically expressed in MSC but not in muscle, cause a severe muscle disorder, Ullrich congenital muscular dystrophy (UCMD). Therefore, we assumed that collagen VI positive MSC could be a cell source of cell therapy for UCMD. However MSC isolated from adult tissues are quite limited in expansion. To overcome such hurdle, we plan to use iPSC-derived MSC for future cell therapy of UCMD. In this symposium, I’ll introduce our recent results which demonstrate that human iPSC-derived MSC could ameliorate the phenotype of UCMD model mice (COL6KO/NSG). |